Tisotumab vedotin

Name: Tisotumab vedotin
Brand: MedChemExpress
SKU: HY-152963
Rating: 4.5 (0 reviews)

Cat. No.: HY-152963 Pureza: 96.34%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer.

Para uso exclusivo en investigación. No vendemos a pacientes.

Tisotumab vedotin Estructura química

No. CAS : 1418731-10-8

Tamaño	Stock	Cantidad
1 mg	En stock	Estimated Time of Arrival: December 31
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	Obtener un presupuesto
50 mg	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 Customer Validation

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

IC₅₀ & Target

tissue factor^[1].

In Vitro

Tisotumab vedotin induces immunogenic cell death in tumor cells expressing TF, leading to the release of endoplasmic reticulum stress markers, ATP, and high mobility histone B1 (HMGB1)^[1].
Tisotumab vedotin induces anti-tumor activity through MMAE mediated cytotoxicity, Fc mediated antibody dependent cell phagocytosis (ADCP), and Fab mediated protease activated receptor 2 (PAR-2) signaling inhibition^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tisotumab vedotin can cause immunogenic tumor cell death, promote activation of F4/80+ and CD11c+ innate immune cells, and recruit them into xenograft tumors^[1].
Tisotumab vedotin (2 mg/kg; once daily; 25 days) has anti-tumor activity in a mouse model of pancreatic cancer^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HPAF-II, SCID mice^[4].
Dosage:	2 mg/kg
Administration:	Once daily; 25 days
Result:	Decreased the tumor volume over the 3-week window.

Ensayo clínico

Peso molecular

152000 (average)

No. CAS

1418731-10-8

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Tisotumab vedotin]

Envío

Shipping with dry ice.

Almacenamiento

-80°C, protect from light

Pureza y Documentación

Purity: 97.20%

Select Batch:

Ficha de datos (268 KB) SDS (251 KB)

COA (231 KB) Others (506 KB) SEC-HPLC (503 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Gray E, et al. Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell deathJournal for ImmunoTherapy of Cancer 2020;8.

[2]. Alley S C, et al. Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro[J]. Cancer Research, 2019, 79(13_Supplement): 221-221.

[3]. Luu K, et al. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin. J Oncol Pharm Pract. 2023 Mar;29(2):441-449. [Content Brief]

[4]. Rubahamya B, et al. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Sci Adv. 2024 May 31;10(22):eadk1894. [Content Brief]